Systemic side effects that result from oral administration of estrogens to postmenopausal women may be minimized by use of the transdemal route.
We administered transdermal estradiol, 50 ug(to 23 postmenopausal women), 100 ug (to 20 postmenopausal women) cyclically for 3 months to 43 postmenopausal women to study the biological effect.
@ES The results were follows:
@EN 1. The plasma estradiol and estrone after transdermal estradiol therapy estradiol therapy in Group II were increased significantly(p<0.05), but difference of changes between two groups was not statistically significant(p>0.05).
2. The plasma FSH and LH after transdermal estradiol therapy in Group I and Group II were decreased significantly(p<0.05), but difference of changes between two groups was not statistically significantly(p>0.05).
3. The change of plasma SHBG and Renin substrate after transdermal estradiol therapy in Group I and Group Ii were not statistically significant (p>0.05), and difference of changes between two groups was not statistically significant(p>0.05).
4. The changes of plasma total cholesterol, triglyceride, and HDL-cholesterol after transdermal estradiol therapy in Group I and Group Ii were not statistically significant (p>0.05) but plasma LDL-cholesterols after transdermal estradiol therapy
in
both groups were statistically significant (p<0.05). The difference of changes betheen two groups was not statistically significant (p>0.05).
5. The changes of urinary calciu, calcuim/creatinine ratio, hydroxyproline/creatinine ratio were not statistically significant in both groups(p<0.05), and the difference of changes between two groups was not statistically significant(p>0.05).
These data indicate that transdermal estradiol can elicit many of the desirable actions of estrogen while avoiding the pharmacologic effects of oral estrogens on hepatic proteins.
|